Companies could create other Covid-prevention drugs. Why aren’t they?; Sarepta to seek early FDA approval for gene therapy to treat Duchenne

Evusheld aside, few other prophylactic drugs for the immunocompromised are on the horizon, despite a potentially large market. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by   STAT+: Drug companies could create new drugs to protect the Covid vulnerable. Why aren't they? By Jason Mast JONATHAN NACKSTRAND/AFP via Getty Images Evusheld aside, few other prophylactic drugs for the immunocompromised are on the horizon, despite a potentially large market. Read More STAT+: Sarepta to seek early FDA approval for gene therapy to treat Duchenne muscular dystrophy By Adam Feuerstein Kristoffer Tripplaar/Sipa via AP The decision to seek accelerated approval is aggressive and carries risk, but could also help Sarepta reach the market much faster. Read More STAT+: A ViiV deal to license its HIV prevention shot to poor countries runs into criticism By Ed Silverman NIAID/NIH Advocacy groups argue the deal could have limited impact due to manufacturing restrictions and pricing uncertainties. Read More Sponsor content by PhRMA 340B is helping big hospitals & chain pharmacies The 340B program was designed to help patients. Instead, it has become less about patients and more about boosting the bottom lines of big hospitals and chain pharmacies. Large hospitals buy deeply discounted 340B medicines and then turn around and charge both uninsured patients and insurance companies higher prices, pocketing the difference with little to no evidence they use that money to help those who actually need it. Does that seem fair to patients? Learn more. Opinion: A better understanding of human diversity is needed to equitably advance precision medicine By David Reese and Kári Stefánsson Adobe Increasing genetic diversity in global databases and biobanks is essential to advancing the field of precision medicine. Read More STAT+: Up and down the ladder: The latest comings and goings By Ed Silverman Alex Hogan/STAT From new hires to departures, promotions, and transfers, here are the latest comings and goings in the pharmaceutical industry. Read More Friday, July 29, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser